格隆汇2月11日｜再鼎医药(ZLAB.US)盘前涨超2.8%，报28.2美元。消息面上，高盛发表研报称，持续看好中国医疗健康板块中的生物科技领域，中国创新力量正在并将持续获全球认可。高盛尤其提及看好再鼎医药DLL3 ADC的BD潜力及2025年实现盈亏平衡拐点，重申其“买入”评级，美股目标价为53.64美元。(格隆汇)

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.